These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26983957)

  • 1. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.
    Bhatt VR
    Curr Hematol Malig Rep; 2016 Jun; 11(3):196-207. PubMed ID: 26983957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.
    Bhatt VR; Armitage JO
    Expert Opin Biol Ther; 2016; 16(1):57-66. PubMed ID: 26515478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
    Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
    Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
    Bhatt VR; Vose JM
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
    Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
    Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
    Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N;
    Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.
    Capria S; Barberi W; Perrone S; Ferretti A; Salaroli A; Annechini G; D'Elia GM; Foà R; Pulsoni A
    Expert Rev Hematol; 2016 Oct; 9(10):951-64. PubMed ID: 27539362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.
    van Besien K
    Curr Opin Oncol; 2011 Nov; 23(6):681-91. PubMed ID: 21946246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Gauthier J; Castagna L; Garnier F; Guillaume T; Socié G; Maury S; Maillard N; Tabrizi R; Marchand T; Malfuson J; Gac A; Gyan E; Mercier M; Béguin Y; Delage J; Turlure P; Marçais A; Nguyen S; Dulery R; Bay J; Huynh A; Daguindau E; Cornillon J; Régny C; Michallet M; Peffault de Latour R; Yakoub-Agha I; Blaise D
    Bone Marrow Transplant; 2017 May; 52(5):689-696. PubMed ID: 28067872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.
    Kim JW; Kim BS; Bang SM; Kim I; Kim DH; Kim WS; Yang DH; Lee JJ; Lee JH; Kim JS; Sohn SK; Yhim HY; Kwak JY; Yoon SS; Lee JS; Park S; Kim BK;
    Ann Hematol; 2011 Dec; 90(12):1409-18. PubMed ID: 21468694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.